Tau Brain Scans in Late-Onset Psychosis Among Older Adults
Studies tau brain scans and blood markers in older people with new hallucinations or delusions.
Key facts
- Who runs it
- Jeremy Koppel
- Where
- Manhasset, United StatesSee the site
- Trial code
- Registry title
- Tau Biomarkers in Late-onset Psychosis (LOP)
- Status
- Recruiting
- People taking part
- 16 people, planned
- Started
- 16 Feb 2024
- Expected to end
- 30 Jun 2027
- Type of study
- Observational
- Treatments tested
- Tau PET imaging scan
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 65 to 85 who first had hallucinations or delusions late in life, with a caregiver who can help. It uses blood tests and a Tau PET scan.
- Age
- 65 to 85 years
- Sex
- Men and women can both join.
- Disease stage
- Late-onset psychosis without mood symptoms: very late-onset schizophrenia-like psychosis or delusional disorder. Dementia rating (CDR) of 0 or 0.5, MMSE score of 24 or more, and normal memory test results.
Main reasons for not taking part
- Mood and psychotic disorders such as bipolar disorder, schizoaffective disorder or active major depression
- Past stroke, epilepsy, Parkinson's disease or other movement disorder, or heart and blood vessel disease
- Alcohol or drug abuse within the last 5 years
- Metal implants such as pacemakers or ear implants
- Cannot lie flat for about 1 hour, or hearing too poor to pass the hearing test
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Male or female, aged 65-85 years
- Diagnosis of late-onset non-affective primary psychotic disorder consistent with either very late-onset schizophrenia-like psychosis (VLOSP, International Late-Onset Schizophrenia Group consensus criteria, Howard et al., 2000) or delusional disorder (DSM-5 criteria)
- Caregiver available to provide collateral history and participation in informant-based ratings (NPI,CDR)
- Clinical Dementia Rating (CDR) score of 0 or 0.5
- Mini-Mental State Examination (MMSE) score ≥ 24 and at the screening visit
- Normal memory function (to rule-out mild cognitive impairment, MCI) documented by scoring within 1.5 SD range in education adjusted norms of the Logical Memory II subscale
- Ability to hear 500, 1000 and 1500 Hz bilaterally on a hearing evaluation (hearing aids permitted)
Who cannot take part
- Presence of metal implants such as pacemakers, ear implants, internal bullet fragments or shrapnel
- Participants with affective and psychotic disorders including bipolar disorder, schizoaffective disorder, active major depression; insulin dependent type 2 diabetes; a history of CVD; a history of epilepsy; a history of TBI with greater than 15 minutes of loss of consciousness; a movement disorder including Parkinson's disease; stroke; autoimmune disease affecting the CNS; substance abuse disorder; or active delirium/encephalopathy
- Evidence of a clinically relevant neurological disorder
- History of alcoholism or drug dependency/abuse within the last 5 years before screening
- Hearing impairment as evidenced by the inability to hear 500, 1000 and 1500 Hz bilaterally on a hearing evaluation. Subjects with hearing aids will be allowed to participate if they meet minimum hearing requirements
- Modified Hachinski ischemia score of more than 4
- Inability to lie flat for 1 hour approximately
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 65 and 85 years old?
Where in United States
- The Feinstein Institutes for Medical ResearchManhasset, United StatesContact: Erica Christen, MSTaking people
About the trial
What the trial wants to find out
Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing.
Treatments tested
- Tau PET imaging scan
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Tau Biomarkers in Late-onset Psychosis (LOP)
- Plain-language title
- Tau Brain Scans in Late-Onset Psychosis Among Older AdultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06336382, who can take part
- Record updated
- 5 November 2026